Literature DB >> 33594805

Optimizing Regorafenib Dosing and Patient Management in Colorectal Cancer in Latin America: Perspectives from Argentina.

Mariano Dioca1, Juan Manuel O'Connor2.   

Abstract

Entities:  

Keywords:  Dosing; Hand-foot skin reaction; Metastatic colorectal cancer; Regorafenib

Mesh：

Substances：

Year:  2021        PMID： 33594805      PMCID： PMC8176974          DOI： 10.1002/onco.13723

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  11 in total

1.  Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.

Authors:  Axel Grothey
Journal:  Clin Adv Hematol Oncol       Date:  2015-08

Review 2.  Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).

Authors:  Roger Anderson; Aminah Jatoi; Caroline Robert; Laura S Wood; Karen N Keating; Mario E Lacouture
Journal:  Oncologist       Date:  2009-03-10

3.  Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.

Authors:  Michel Ducreux; Lone Nørgård Petersen; Leopold Öhler; Francesca Bergamo; Jean-Philippe Metges; Jan Willem de Groot; Jaw-Yuan Wang; Beatriz García Paredes; Emmanuelle Dochy; Sabine Fiala-Buskies; Andrés Cervantes; Juan Manuel O'Connor; Alfredo Falcone
Journal:  Eur J Cancer       Date:  2019-11-04       Impact factor: 9.162

4.  Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.

Authors:  Scott M Wilhelm; Jacques Dumas; Lila Adnane; Mark Lynch; Christopher A Carter; Gunnar Schütz; Karl-Heinz Thierauch; Dieter Zopf
Journal:  Int J Cancer       Date:  2011-04-22       Impact factor: 7.396

5.  Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jin Li; Shukui Qin; Ruihua Xu; Thomas C C Yau; Brigette Ma; Hongming Pan; Jianming Xu; Yuxian Bai; Yihebali Chi; Liwei Wang; Kun-Huei Yeh; Feng Bi; Ying Cheng; Anh Tuan Le; Jen-Kou Lin; Tianshu Liu; Dong Ma; Christian Kappeler; Joachim Kalmus; Tae Won Kim
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

6.  Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

Authors:  Axel Grothey; Suzanne George; Eric van Cutsem; Jean-Yves Blay; Alberto Sobrero; George D Demetri
Journal:  Oncologist       Date:  2014-05-12

7.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

Review 8.  Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.

Authors:  Tanios Bekaii-Saab; Richard Kim; Tae Won Kim; Juan Manuel O'Connor; John H Strickler; David Malka; Andrea Sartore-Bianchi; Feng Bi; Kensei Yamaguchi; Takayuki Yoshino; Gerald W Prager
Journal:  Clin Colorectal Cancer       Date:  2018-11-16       Impact factor: 4.481

9.  Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Authors:  Tanios S Bekaii-Saab; Fang-Shu Ou; Daniel H Ahn; Patrick M Boland; Kristen K Ciombor; Erica N Heying; Travis J Dockter; Nisha L Jacobs; Boris C Pasche; James M Cleary; Jeffrey P Meyers; Rodwige J Desnoyers; Jeannine S McCune; Katrina Pedersen; Afsaneh Barzi; E Gabriela Chiorean; Jeffrey Sloan; Mario E Lacouture; Heinz-Josef Lenz; Axel Grothey
Journal:  Lancet Oncol       Date:  2019-06-28       Impact factor: 54.433

10.  Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series.

Authors:  José Luis Leal; Juan Briones; María Elisa Herrera; Bettina Müller; Bruno Nervi; Sebastián Mondaca
Journal:  Ecancermedicalscience       Date:  2018-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.